Low-Grade Serous Ovarian Cancer Clinical Trials
What are Clinical Studies?
Low-grade serous ovarian and peritoneal cancer clinical studies are a type of research that people can volunteer to participate in to further medical knowledge about low-grade serous carcinoma.
Studies can be interventional (a clinical trial where participation could change someone’s medical management) or observational (an observational study where data about a person is collected over time but participation in the study does not influence how they are treated). Both types of clinical research are important to improve future prevention, diagnosis, survival and quality of life of people with low-grade serous carcinoma.
Studies may recruit people who are newly diagnosed, or have recurred or are at any point from diagnosis.
Potential Benefits and Risks of Clinical Trials
Potential benefits of participating in a clinical trial could include*:
- Helping people with your cancer
- Accessing new treatments
- Close monitoring by your medical team
Potential risks of participating in a clinical trial could include*:
- Like any test or treatment there may be side effects
- New tests or treatments may not work
- More hospital visits
*Modified from the 2017 NCCN Guidelines
Ways to find a Clinical Study
If you are interested in participating in a clinical trial or observational study you can search a clinical trials database and review our list of low-grade serous cancer clinical trials below.
If your country does not have a low-grade serous specific study that you can participate in – there may still be multi-cancer trials available.
1. Find a low-grade serous cancer trial by searching a Clinical Trial Databases
Useful Search Terms
Useful search terms for finding low-grade serous ovarian and peritoneal cancer clinical studies include: “low grade serous”, “low grade serous ovarian cancer”, “low grade serous carcinoma”, “low grade serous adenocarcinoma”, “LGSOC” and “LGSC”.
Clinical Trial Databases
- ClinicalTrials.gov a resource provided by the U.S. National Library of Medicine that lists trials across 207 countries.
- International Clinical Trials Registry Platform hosted by the World Health Organisation
- EU Clinical Trials Register lists trials based in the European Union
- Be Part of Research UK for UK specific trials
- ANZCTR trials database for Australia and New Zealand
- Canadian Cancer Trials Canadian trials
- ISRCTN an international registry of clinical trials
- OCRA Clinical Trials Navigation Service (US only)
2. Review our list of low-grade serous carcinoma specific clinical trials
Please note trial locations in italics are indicative only and may change over time. For the most up to date information please click on the linked trial.
Trials for people newly diagnosed with low-grade serous cancer
- Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer (Mentioned in this article) (US, Canada, Korea)
- Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous (recruitment closed 2022 – initial results)
- Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (PARAGON-II) (Australia)
- MAintenance Therapy With Aromatase Inhibitor (AI) in Epithelial Ovarian Cancer (MATAO) (People in this study could be randomised to a treatment option of chemotherapy with no maintenance therapy. Findings from a 2022 retrospective study suggest that people who receive AI maintenance therapy may have a reduced risk of recurrence. To help you decide if this study is right for you, you may want to ask your doctor to help you interpret the original research paper in the context of this clinical trial) (Austria, Switzerland)
- Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) (People in this study could be randomised to a treatment option of chemotherapy with no maintenance therapy. See comment above.) (Italy)
Trials for people experiencing recurrence/progression of low-grade serous cancer
- A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (Also known as Ramp 201 this is a Phase 2 trial, related to the Phase 1 FRAME trial listed below. Early results from the trial are available here. At the time of last update the single therapy arm had closed but recruitment was continuing for the dual therapy arm (VS-6766 and Defactinib). For additional information see https://ramp201study.com) (Belgium, Canada, France, Italy, Spain, UK, US)
- Phase I Trial of VS-6063 and RO5126766. (FRAME) (see updated results) (UK)
- Ribociclib and Letrozole Treatment in Ovarian Cancer (Initial results of a similar trial in newly diagnosed people using another type of CDK4/6 & hormonal therapy treatment combination can be found here) (US)
- Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (PARAGON-II) (Australia)
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer (not yet recruiting as of Jan’22) (US)
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (not yet recruiting as of Dec ’22)
- A Study of Onapristone ER in Low Grade Serous Ovarian Cancer and Other Progesterone Receptor Positive Gynecologic Cancers (no longer recruiting)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (US and Puerto Rico)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (US, Australia, Belgium, Canada, Czechia, France, Germany, Italy, Korea, Russia, Spain, Switzerland, Turkey, UK)
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION) (Germany)
- A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients (Recruitment suspended Nov 2021)
- Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC) (Australia only)
Observational Data Collection Studies for low grade serous cancer
- Data Collection for Patients with Low Grade Ovarian Carcinoma (MD Anderson, US)
- Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22) (Italy)
- Cart-Wheel Rare Cancer Database (Australia and New Zealand)
3. Find a Multi-Cancer Trial that accepts low-grade serous cancer
In addition to low-grade serous specific trials, some people with low-grade serous carcinoma may also qualify for broader cancer trials that accept many types of cancer, or cancers with specific mutations.
Useful search terms for multi-cancer trials
Useful search terms to find multi-cancer clinical studies that may also accept people with low-grade serous carcinoma include “ovarian cancer” or “solid tumor” with “ER(+)” or “MEK inhibitor” or the name of any specific genetic mutations identified (e.g. KRAS).
Below are a few examples of some of the types of multi-cancer trials that might accept people with low-grade serous cancer.
- Ovarian cancer trial: A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer (no longer recruiting: interim results here)
- Mutation specific trial (KRAS G12C): JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
- Multi-cancer trial: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Multi-cancer trial including MEK inhibitor: Selumetinib and Olaparib in Solid Tumors (recruitment closed)
The best way to find a multi-cancer trial is to speak to your doctor or search one of the clinical trials databases mentioned earlier on this page.
Disclaimer
Cure Our Ovarian Cancer is not directly affiliated with any of the above databases or clinical trials. The information on this page is for general purposes only and not a replacement for medical advice. Clinical trials may have unique risks and unknown benefits which the clinical trial researchers and your doctor can help you understand.
Page updated Feb 2023
